Anthony J. Guzzo - Jan 19, 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Signature
/s/ Larry Miller, Attorney-in-Fact for Anthony J. Guzzo
Stock symbol
PHAT
Transactions as of
Jan 19, 2022
Transactions value $
$0
Form type
4
Date filed
1/21/2022, 05:49 PM
Previous filing
Jun 11, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award $0 +6K +250.1% $0.00 8.4K Jan 19, 2022 Direct F1, F2
holding PHAT Common Stock 464 Jan 19, 2022 by 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Stock Option (Right to Buy) Award $0 +30K $0.00 30K Jan 19, 2022 Common Stock 30K $15.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Includes 2,399 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022.
F3 The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.